AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by equities researchers at Shore Capital in a research note issued on Friday.

A number of other equities research analysts have also weighed in on the company. Citigroup Inc. reissued a “buy” rating and issued a GBX 6,000 ($77.89) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG lowered their target price on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,350 ($69.45) and set a “buy” rating for the company in a research note on Friday, April 28th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,000 ($77.89) target price on shares of AstraZeneca plc in a research note on Friday, April 28th. Jefferies Group LLC lowered their target price on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,300 ($68.80) and set a “hold” rating for the company in a research note on Wednesday, July 12th. Finally, HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.42) target price for the company. in a research note on Tuesday, July 4th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 4,932.67 ($64.04).

Shares of AstraZeneca plc (AZN) opened at 4462.00 on Friday. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The company’s 50-day moving average price is GBX 4,840.03 and its 200 day moving average price is GBX 4,866.25. The firm’s market cap is GBX 56.49 billion.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/18/astrazeneca-plcs-azn-hold-rating-reiterated-at-shore-capital.html.

In other news, insider Nazneen Rahman bought 39 shares of AstraZeneca plc stock in a transaction on Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.